Financial Results & Release Schedules, Stock Performance Update, and New Clinical Trials - Research Report on Amgen, Boston Scientific, ACADIA Pharmaceuticals, Seattle Genetics, and Volcano

NEW YORK, October 29, 2013 /PRNewswire/ --

Today, Analysts' Corner announced new research reports highlighting Amgen, Inc. (NASDAQ: AMGN), Boston Scientific Corporation (NYSE: BSX), ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), Seattle Genetics, Inc. (NASDAQ: SGEN), and Volcano Corporation (NASDAQ: VOLC). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.

Boston Scientific Corporation Research Report

On October 24, 2013, Boston Scientific Corporation (Boston Scientific) reported its Q3 2013 financial results. The Company's net sales remained unchanged at $1.7 billion during the quarter on YoY basis. Net loss was $5 million or $0.00 per diluted share in Q3 2013, compared to net loss of $664 million or $0.48 per diluted share in Q3 2012. Commenting on the results, Mike Mahoney, Boston Scientific's President and CEO, said, "We are pleased with our strong overall results and the momentum we are building globally in a dynamic healthcare environment. We accelerated our operational performance in the quarter while enhancing our ability to deliver meaningful innovation to our customers and their patients." Additionally, the Company announced that Jeffrey Capello, Boston Scientific's Executive Vice President and CFO, will transition out of the role, effective December 31, 2013, while Daniel Brennan will take over his responsibilities, effective January 1, 2014. Meanwhile, Capello is expected to remain with the Company as a Senior Advisor until mid-May 2014. The Full Research Report on Boston Scientific Corporation - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/5640_BSX]

--

Amgen, Inc. Research Report

On October 22, 2013, Amgen, Inc. (Amgen) reported its Q3 2013 financial results. The Company's total revenues increased 9.9% YoY to $4.7 billion during the quarter. The Company's net income was $1.4 billion or $1.79 per diluted share in Q3 2013, compared to net income of $1.1 billion or $1.41 per diluted share in Q3 2012. Commenting on the results, Robert A. Bradway, Chairman and CEO of Amgen, said, "We delivered excellent operating performance this quarter. We also delivered excellent strategic progress with the acquisition of Onyx Pharmaceuticals in oncology, the opening of our alliances in Japan and China, and the repurchase of our rights to NEUPOGEN and Neulasta in key emerging growth markets around the world." The Full Research Report on Amgen, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/e96b_AMGN]

--

ACADIA Pharmaceuticals Inc. Research Report

On October 24, 2013, ACADIA Pharmaceuticals Inc.'s (ACADIA Pharmaceuticals) stock gained 12.31%, ending the day at $24.73. Over the previous three trading sessions, shares of ACADIA Pharmaceuticals gained 7.20%, outperforming the Nasdaq Composite which gained 0.23% during the same period. The Full Research Report on ACADIA Pharmaceuticals Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/3eb7_ACAD]

--

Seattle Genetics, Inc. Research Report

On October 21, 2013, Seattle Genetics, Inc. (Seattle Genetics) announced the initiation of a phase 1 clinical trial evaluating SGN-LIV1A for patients with LIV-1-positive metastatic breast cancer. The Company said that SGN-LIV1A uses Seattle Genetics' antibody-drug conjugate (ADC) technology, and the trial is meant to assess the safety and antitumor activity of SGN-LIV1A, an ADC targeted to LIV-1 (SLC39A6), a protein which is expressed in most subtypes of metastatic breast cancer. Jonathan Drachman, M.D., Chief Medical Officer and Executive Vice President, Research and Development, at Seattle Genetics, said, "ADCs represent a novel treatment approach that have demonstrated activity in both hematologic and solid tumors. SGN-LIV1A is one of four ADCs that we are advancing into the clinic during 2013, demonstrating our significant investment in this approach for the treatment of cancer. The target expression in breast cancer, preclinical antitumor activity, and need for novel therapeutic options for advanced breast cancer patients all support the clinical evaluation of SGN-LIV1A." The Full Research Report on Seattle Genetics, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/ff98_SGEN]

--

Volcano Corporation Research Report

On October 21, 2013, Volcano Corporation (Volcano) announced that the Company will report its operating results for Q3 2013 on Monday, November 4, 2013. The Company stated that it will also hold a conference call to discuss its financial results and operating activities on the same day at 2:00 p.m. PST (5:00 p.m. EST), hosted by Volcano's President and CEO, Scott Huennekens and CFO John Dahldorf. The Full Research Report on Volcano Corporation - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/14bf_VOLC]

----

EDITOR NOTES:

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
2. Information in this release is fact checked and produced on a best efforts basis and reviewed by Namrata Maheshwari, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at [email protected].
5. For any urgent concerns or inquiries, please contact us at [email protected].
6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to [email protected] for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Namrata Maheshwari, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

AnalystsCorner.com

SOURCE Analysts' Corner